Petrylak, D., Eigl, B., Senkus, E., Loriot, Y., Twardowski, P., Castellano, D., Blais, N., Sridhar, S., Sternberg, C., Retz, M., Blumenstein, B., Jacobs, C., Stewart, P., & Bellmunt, J. (n.d.). 2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo. European journal of cancer, 51, S525–. http://access.bl.uk/ark:/81055/vdc_100030628262.0x000062